+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Community-Acquired Bacterial Pneumonia (CABP) - Market Insight, Epidemiology and Market Forecast -2032

  • PDF Icon

    Report

  • 160 Pages
  • January 2022
  • Region: Global
  • DelveInsight
  • ID: 5523887
This "Community-Acquired Bacterial Pneumonia (CABP)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia (CABP), historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia (CABP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Community-Acquired Bacterial Pneumonia (CABP) market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia (CABP) market share of the individual therapies, current and forecasted Community-Acquired Bacterial Pneumonia (CABP) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Community-Acquired Bacterial Pneumonia (CABP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Community-Acquired Bacterial Pneumonia (CABP) Disease Understanding and Treatment Algorithm


The Community-Acquired Bacterial Pneumonia (CABP) market report gives a thorough understanding of the Community-Acquired Bacterial Pneumonia (CABP) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Community-Acquired Bacterial Pneumonia (CABP).

Treatment


It covers the details of conventional and current medical therapies available in the Community-Acquired Bacterial Pneumonia (CABP) market for the treatment of the condition. It also provides Community-Acquired Bacterial Pneumonia (CABP) treatment algorithms and guidelines in the United States, Europe, and Japan.

Community-Acquired Bacterial Pneumonia (CABP) Epidemiology


The Community-Acquired Bacterial Pneumonia (CABP) epidemiology division provide insights about historical and current Community-Acquired Bacterial Pneumonia (CABP) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Community-Acquired Bacterial Pneumonia (CABP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Community-Acquired Bacterial Pneumonia (CABP) Epidemiology


The epidemiology segment also provides the Community-Acquired Bacterial Pneumonia (CABP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Community-Acquired Bacterial Pneumonia (CABP) Drug Chapters


Drug chapter segment of the Community-Acquired Bacterial Pneumonia (CABP) report encloses the detailed analysis of Community-Acquired Bacterial Pneumonia (CABP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Community-Acquired Bacterial Pneumonia (CABP) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Community-Acquired Bacterial Pneumonia (CABP) treatment.

Community-Acquired Bacterial Pneumonia (CABP) Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Community-Acquired Bacterial Pneumonia (CABP) treatment.

Community-Acquired Bacterial Pneumonia (CABP) Market Outlook


The Community-Acquired Bacterial Pneumonia (CABP) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Community-Acquired Bacterial Pneumonia (CABP) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Community-Acquired Bacterial Pneumonia (CABP) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Community-Acquired Bacterial Pneumonia (CABP) market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Community-Acquired Bacterial Pneumonia (CABP) market in 7MM.

The United States Market Outlook


This section provides the total Community-Acquired Bacterial Pneumonia (CABP) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Community-Acquired Bacterial Pneumonia (CABP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Community-Acquired Bacterial Pneumonia (CABP) market size and market size by therapies in Japan is also mentioned.

Community-Acquired Bacterial Pneumonia (CABP) Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia (CABP) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Community-Acquired Bacterial Pneumonia (CABP) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Community-Acquired Bacterial Pneumonia (CABP) Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Community-Acquired Bacterial Pneumonia (CABP) key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Community-Acquired Bacterial Pneumonia (CABP) emerging therapies.

Reimbursement Scenario in Community-Acquired Bacterial Pneumonia (CABP)


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Community-Acquired Bacterial Pneumonia (CABP) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Community-Acquired Bacterial Pneumonia (CABP) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Community-Acquired Bacterial Pneumonia (CABP) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Community-Acquired Bacterial Pneumonia (CABP), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Community-Acquired Bacterial Pneumonia (CABP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Community-Acquired Bacterial Pneumonia (CABP) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Community-Acquired Bacterial Pneumonia (CABP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Community-Acquired Bacterial Pneumonia (CABP) market

Report Highlights

  • In the coming years, Community-Acquired Bacterial Pneumonia (CABP) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Community-Acquired Bacterial Pneumonia (CABP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Community-Acquired Bacterial Pneumonia (CABP). Launch of emerging therapies will significantly impact the Community-Acquired Bacterial Pneumonia (CABP) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Community-Acquired Bacterial Pneumonia (CABP)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Community-Acquired Bacterial Pneumonia (CABP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Community-Acquired Bacterial Pneumonia (CABP) Pipeline Analysis
  • Community-Acquired Bacterial Pneumonia (CABP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Community-Acquired Bacterial Pneumonia (CABP) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Community-Acquired Bacterial Pneumonia (CABP) Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Community-Acquired Bacterial Pneumonia (CABP) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Community-Acquired Bacterial Pneumonia (CABP) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Community-Acquired Bacterial Pneumonia (CABP) market size during the forecast period (2019-2032)?
  • At what CAGR, the Community-Acquired Bacterial Pneumonia (CABP) market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Community-Acquired Bacterial Pneumonia (CABP) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Community-Acquired Bacterial Pneumonia (CABP) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Community-Acquired Bacterial Pneumonia (CABP)?
  • What is the historical Community-Acquired Bacterial Pneumonia (CABP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Community-Acquired Bacterial Pneumonia (CABP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Community-Acquired Bacterial Pneumonia (CABP)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Community-Acquired Bacterial Pneumonia (CABP) during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Community-Acquired Bacterial Pneumonia (CABP) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Community-Acquired Bacterial Pneumonia (CABP) in the USA, Europe, and Japan?
  • What are the Community-Acquired Bacterial Pneumonia (CABP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Community-Acquired Bacterial Pneumonia (CABP)?
  • How many therapies are developed by each company for Community-Acquired Bacterial Pneumonia (CABP) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Community-Acquired Bacterial Pneumonia (CABP) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Community-Acquired Bacterial Pneumonia (CABP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Community-Acquired Bacterial Pneumonia (CABP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Community-Acquired Bacterial Pneumonia (CABP)?
  • What are the global historical and forecasted market of Community-Acquired Bacterial Pneumonia (CABP)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Community-Acquired Bacterial Pneumonia (CABP) market
  • To understand the future market competition in the Community-Acquired Bacterial Pneumonia (CABP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Community-Acquired Bacterial Pneumonia (CABP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Community-Acquired Bacterial Pneumonia (CABP) market
  • To understand the future market competition in the Community-Acquired Bacterial Pneumonia (CABP) market

Table of Contents

1. Key Insights2. Report Introduction
3. Community-Acquired Bacterial Pneumonia (CABP) Market Overview at a Glance
3.1. Market Share (%) Distribution Community-Acquired Bacterial Pneumonia (CABP) in 2019
3.2. Market Share (%) Distribution of Community-Acquired Bacterial Pneumonia (CABP) in 2032
4. Executive Summary of Community-Acquired Bacterial Pneumonia (CABP)
5. Disease Background and Overview
5.1. Introduction
5.2. Etiology
5.3. Pathophysiology
5.4. Signs and Symptoms of CABP
5.5. Clinical Characteristics
5.6. Immunology & Risk Factors
5.7. Diagnosis
5.8. Prognosis
5.9. Diagnostic Biomarkers for CABP
6. Treatment and Management
6.1. Antibiotic therapy
6.2. Diuretics
6.3. Corticosteroids
6.4. Later management
6.5. Diagnostic and Treatment Guidelines
6.5.1. The American Thoracic Society and the Infectious Diseases Society of America
6.5.2. NICE
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total Incident Patient Population of Community-Acquired Bacterial Pneumonia (CABP)
7.3. Assumptions and Rationale
7.4. The United States
7.4.1. Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the United States
7.4.2. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the United States
7.4.3. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the United States
7.4.4. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in the United States
7.4.5. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in the United States
7.5. The EU-5
7.5.1. Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5
7.5.2. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the EU-5
7.5.3. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the EU-5
7.5.4. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in EU-5
7.5.5. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in EU-5
7.6. Japan
7.6.1. Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in Japan
7.6.2. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in Japan
7.6.3. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in Japan
7.6.4. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in Japan
7.6.5. Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in Japan
8. Patient Journey 19. Patient Journey 2
10. Marketed Therapies
10.1. Lefamulin (Xenleta): Nabriva Therapeutics
10.1.1. Product Description
10.1.2. Regulatory Milestones
10.1.3. Other Developmental Activities
10.1.4. Clinical Development
10.1.5. Product Profile
10.2. Delafloxacin - Melinta Therapeutics/Wakunaga Pharmaceutical
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Developmental Activities
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
10.2.6. Product Profile
10.3. Ceftaroline fosamil (Teflaro): Forest Pharmaceuticals
10.3.1. Drug Description
10.3.2. Regulatory Milestones
10.3.3. Other Development Activities
10.3.4. Clinical Development
10.3.5. Clinical Trials Information
10.3.6. Safety and efficacy
10.3.7. Product Profile
10.4. Linezolid (Zyvox): Pfizer
10.4.1. Drug Description
10.4.2. Regulatory Milestones
10.4.3. Clinical Development
10.4.4. Clinical Trials Information
10.4.5. Product Profile
10.5. Omadacycline (NUZYRA): Paratek Pharmaceuticals
10.5.1. Drug Description
10.5.2. Regulatory Milestones
10.5.3. Other Development Activities
10.5.4. Clinical Development
10.5.5. Clinical Trials Information
10.5.6. Safety and efficacy
10.5.7. Product Profile
10.6. Telavancin (Vibativ): Cumberland Pharmaceuticals Inc./Theravance Biopharma
10.6.1. Drug Description
10.6.2. Regulatory Milestones
10.6.3. Other Development Activities
10.6.4. Clinical Development
10.6.5. Clinical Trials Information
10.6.6. Safety and efficacy
10.6.7. Product Profile
10.7. Ceftolozane/Tazobactam (Zerbaxa): Merck Sharp & Dohme Inc./Cubist Pharmaceuticals LLC
10.7.1. Drug Description
10.7.2. Regulatory Milestones
10.7.3. Clinical Development
10.7.4. Clinical Trials Information
10.7.5. Safety and efficacy
10.7.6. Product Profile
10.8. Imipenem/Cilastatin/Relebactam (Recarbrio™): Merck Sharp and Dohme
10.8.1. Product Description
10.8.2. Regulatory Milestones
10.8.3. Clinical Development
10.8.4. Safety and Efficacy
10.8.5. Product Profile
10.9. Cefiderocol ( Fetroja®): Shionogi Inc.
10.9.1. Product Description
10.9.2. Regulatory Milestones
10.9.3. Clinical Development
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. Ceftazidime/Avibactam (Avycaz): Allergan/Pfizer
10.10.1. Product Description
10.10.2. Regulatory Milestones
10.10.3. Other Developmental Activities
10.10.4. Clinical Development
10.10.5. Safety and Efficacy
10.10.6. Product Profile
11. Emerging Drugs
11.1. CAL02: Eagle Pharmaceutical Inc/Combioxin SA
11.1.1. Drug Description
11.1.2. Other Development Activities
11.1.3. Clinical Development
11.1.4. Clinical Trials Information
11.1.5. Safety and efficacy
11.1.6. Product Profile
11.2. Cx611: Takeda/TiGenix
11.2.1. Drug Description
11.2.2. Other Development Activities
11.2.3. Clinical Development
11.2.4. Clinical Trials Information
11.2.5. Safety and efficacy
11.2.6. Product Profile
12. Other Therapies: Generics
12.1. Amoxicillin
12.2. Azithromycin
12.3. Clarithromycin
12.4. Doxycycline
12.5. Moxifloxacin
12.6. Vaccine
12.6.1. Prevnar 13
12.6.2. Vaxneuvance
13. Community-Acquired Bacterial Pneumonia: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the 7 MM
13.3. Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies In 7MM
14. Market Outlook
14.1. The United States Market Size
14.1.1. Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States
14.1.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the United States
14.2. The EU-5 Market Size
14.2.1. Total Market size of Community-Acquired Bacterial Pneumonia (CABP) in EU-5
14.2.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) of Therapies in EU-5
14.3. Japan Market Size
14.3.1. Total Market size of Community-Acquired Bacterial Pneumonia (CABP) in Japan
14.3.2. Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in Japan
15. KOL Views16. Unmet Needs17. SWOT Analysis
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. Capabilities20. Disclaimer21. About the Publisher
List of Tables
Table 1: Summary of Community-Acquired Bacterial Pneumonia (CABP), Market, Epidemiology, and Key Events (2019-2032)
Table 2: Incidence of Community-Acquired Bacterial Pneumonia (CABP) in 7MM in 000’s (2019-2032)
Table 3: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the United States in 000’s (2019-2032)
Table 4: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the United States in 000’s (2019-2032)
Table 5: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the United States in 000’s (2019-2032)
Table 6: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in the United States in 000’s (2019-2032)
Table 7: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in the United States in 000’s (2019-2032)
Table 8: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in EU-5 in 000's (2019-2032)
Table 9: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the EU-5 in 000's (2019-2032)
Table 10: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the EU-5 in 000’s (2019-2032)
Table 11: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in EU-5 in 000’s (2019-2032)
Table 12: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in EU-5 in 000’s (2019-2032)
Table 13: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in Japan in 000's (2019-2032)
Table 14: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in Japan in 000's (2019-2032)
Table 15: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in Japan in 000's (2019-2032)
Table 16: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in Japan in 000’s (2019-2032)
Table 17: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in Japan in 000's (2019-2032)
Table 18: Ceftaroline fosamil, Clinical Trial Description, 2022
Table 19: Linezolid, Clinical Trial Description, 2022
Table 20: Omadacycline, Clinical Trial Description, 2022
Table 21: Vibativ, Clinical Trial Description, 2022
Table 22: Zerbaxa, Clinical Trial Description, 2022
Table 23: CAL02, Clinical Trial Description, 2022
Table 24: Cx611, Clinical Trial Description, 2022
Table 25: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in USD Million in 7MM (2019-2032)
Table 26: 7 Major Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in USD Million (2019-2032)
Table 27: United States Market Size of Community-Acquired Bacterial Pneumonia (CABP) in USD Million (2019-2032)
Table 28: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the US in USD Million (2019-2032)
Table 29: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5 in USD Million (2019-2032)
Table 30: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the EU-5 in USD Million (2019-2032)
Table 31: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in Japan in USD Million (2019-2032)
Table 32: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in Japan in USD Million (2019-2032)
List of Figures
Figure 1: Types of Bacterial Pneumonia
Figure 2: Etiology of Community-acquired Pneumonia
Figure 3: Summary of the diagnostic approach to acute cough illness in ambulatory patients.
Figure 4: Chest radiograph demonstrating lobar pneumonia
Figure 5: Clinical decision rules
Figure 6: Incident Patient Population of Community-Acquired Bacterial Pneumonia (CABP) in 7MM in 000’s (2019-2032)
Figure 7: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the United States in 000’s (2019-2032)
Figure 8: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the United States in 000’s (2019-2032)
Figure 9: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the United States in 000’s (2019-2032)
Figure 10: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in the United States in 000’s (2019-2032)
Figure 11: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in the United States in 000’s (2019-2032)
Figure 12: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5 in 000's (2019-2032)
Figure 13: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in the EU-5 in 000's (2019-2032)
Figure 14: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in the EU-5 in 000’s (2019-2032)
Figure 15: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in EU-5 in 000’s (2019-2032)
Figure 16: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in EU-5 in 000’s (2019-2032)
Figure 17: Incident Cases of Community-Acquired Bacterial Pneumonia (CABP) in Japan in 000's (2019-2032)
Figure 18: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Gender in Japan in 000's (2019-2032)
Figure 19: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Severity in Japan in 000's (2019-2032)
Figure 20: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Pathogens in Japan in 000’s (2019-2032)
Figure 21: Incidence of Community-Acquired Bacterial Pneumonia (CABP) based on Age in Japan in 000's (2019-2032)
Figure 22: 7 Major Market Size of Community-Acquired Bacterial Pneumonia (CABP) in USD Million (2019-2032)
Figure 23: 7 Major Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in USD Million (2019-2032)
Figure 24: Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the United States, USD Million (2019-2032)
Figure 25: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the US in USD Million (2019-2032)
Figure 26: Total Market Size of Community-Acquired Bacterial Pneumonia (CABP) in the EU-5, USD Million (2019-2032)
Figure 27: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in the EU-5 in USD Million (2019-2032)
Figure 28: Market Size of Community-Acquired Bacterial Pneumonia (CABP) in Japan, USD Million (2019-2032)
Figure 29: Market Size of Community-Acquired Bacterial Pneumonia (CABP) by Therapies in Japan in USD Million (2019-2032)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Nabriva Therapeutics
  • Melinta Therapeutics
  • Wakunaga Pharmaceutical
  • Forest Pharmaceuticals
  • Pfizer
  • Paratek Pharmaceuticals
  • Cumberland Pharmaceuticals Inc.
  • Theravance Biopharma
  • Merck Sharp & Dohme Inc.
  • Cubist Pharmaceuticals LLC
  • Shionogi Inc.
  • Allergan
  • Eagle Pharmaceutical Inc
  • Combioxin SA
  • Takeda
  • TiGenix